comparemela.com
Home
Live Updates
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023 : comparemela.com
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023
Results confirm promising clinical activity, durable responses and favorable safety of lacutamab in heavily pretreated post-mogamulizumab Sézary Syndrome…
Related Keywords
Colorado
,
United States
,
France
,
North Vancouver
,
British Columbia
,
Canada
,
New York
,
Toronto
,
Ontario
,
Denver
,
Philadelphia
,
Pennsylvania
,
California
,
Rockville
,
Ottawa
,
San Diego
,
French
,
Henry Wheeler
,
Joe Oconnor
,
Barbara Shecter
,
Arthur Rouill
,
Sonia Quaratino
,
Gabriel Friedman
,
Pierluigi Porcu
,
French Financial Markets Authority
,
Exchange Commission
,
Twitter
,
European Medicines Agency
,
Astrazeneca
,
National Post
,
Company Annual Report On Form
,
Postmedia Network Inc
,
Division Of Hematologic Malignancies
,
Canada Revenue Agency
,
Sidney Kimmel Cancer Center
,
Jefferson Health
,
Drug Administration
,
Euronext
,
European Union
,
Linkedin
,
Nasdaq
,
Business Wire
,
With Lacutamab
,
Innate Pharma
,
Euronext Paris
,
Joeo Connor
,
Victoria Wells
,
Financial Times
,
Financial Post
,
New York Times
,
Chief Medical Officer
,
Hematologic Malignancies
,
Hematopoietic Stem Cell Transplantation
,
Principal Investigator
,
Postmedia Network
,
Top Stories
,
Fast Track
,
Engager Therapeutics
,
Private Securities Litigation Reform Act
,
Risk Factors
,
Universal Registration Document
,
Annual Report
,
Yonge Street
,
Amazon Prime
,
comparemela.com © 2020. All Rights Reserved.